| Name | Value |
|---|---|
| Revenues | 659.9M |
| Cost of Revenue | 463.0M |
| Gross Profit | 196.9M |
| Operating Expense | 55.1M |
| Operating I/L | 141.8M |
| Other Income/Expense | 1.0M |
| Interest Income | 1.5M |
| Pretax | 142.8M |
| Income Tax Expense | 31.7M |
| Net Income/Loss | 111.1M |
Medpace Holdings, Inc. provides comprehensive clinical research-based drug and medical device development services globally. The company offers a range of services supporting the clinical development process from Phase I to Phase IV across various therapeutic areas. Its services include clinical development, project management, regulatory affairs, data management and analysis, pharmacovigilance, new drug application submissions, and post-marketing clinical support. Additionally, it provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace generates revenue by offering these services to pharmaceutical, biotechnology, and medical device industries.